Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference25 articles.
1. Tumor angiogenesis: therapeutic implications;Folkman;N Engl J Med,1971
2. Thalidomide is an inhibitor of angiogenesis;D’Amato;Proc Natl Acad Sci USA,1997
3. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization;Kenyon;Exp Eye Res,1997
4. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer;Salven;Int J Cancer,1998
5. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis;Ueno;Lung Cancer,2001
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pomalidomide sensitizes lung cancer cells to TRAIL/CDDP-induced apoptosis via directly targeting electron transfer flavoprotein alpha subunit;Bioorganic Chemistry;2024-12
2. Phase II trials;A Concise Guide to Clinical Trials;2024-05-10
3. Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454–3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC;Chemico-Biological Interactions;2021-11
4. Angiogenesis Inhibitors in Small Cell Lung Cancer;Frontiers in Oncology;2021-05-28
5. Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer;Journal of Drug Targeting;2020-07-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3